In-vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations

被引:71
作者
Cavusoglu, C [1 ]
Karaca-Derici, Y [1 ]
Bilgic, A [1 ]
机构
[1] Ege Univ, Fac Med, Izmir, Turkey
关键词
Mycobacterium tuberculosis; resistance; rifabutin; rifampicin; rpoB;
D O I
10.1111/j.1469-0691.2004.00917.x
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The relationship between resistance to rifampicin and rifabutin and genetic alterations in the rpoB gene of 41 rifampicin-resistant isolates of Mycobacterium tuberculosis was evaluated. Although 35 isolates with rifampicin MICs greater than or equal to 32 mg/L were also rifabutin-resistant, six isolates with rifampicin MICs of 2-16 mg/L were susceptible to rifabutin (MIC less than or equal to 0.5 mg/L). Mutations Asp516Val, Asp516Tyr, Leu533Pro and the double mutation Met515Ile and Leu533Pro influenced susceptibility to rifampicin, but not to rifabutin. All mutations at codons 531 and 526, except one isolate with a His526Cys mutation, correlated with resistance to both compounds.
引用
收藏
页码:662 / 665
页数:5
相关论文
共 20 条
[1]  
Bennett JE, 2000, PRINCIPLES PRACTICE, V5th, P348
[2]   MUTATION POSITION AND TYPE OF SUBSTITUTION IN THE BETA-SUBUNIT OF THE RNA-POLYMERASE INFLUENCE IN-VITRO ACTIVITY OF RIFAMYCINS IN RIFAMPICIN-RESISTANT MYCOBACTERIUM-TUBERCULOSIS [J].
BODMER, T ;
ZURCHER, G ;
IMBODEN, P ;
TELENTI, A .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1995, 35 (02) :345-348
[3]   Characterization of rpoB mutations in rifampin-resistant clinical isolates of Mycobacterium tuberculosis from turkey by DNA sequencing and line probe assay [J].
Cavusoglu, C ;
Hilmioglu, S ;
Guneri, S ;
Bilgic, A .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (12) :4435-4438
[4]   INVITRO ACTIVITY OF NEW RIFAMYCINS AGAINST RIFAMPICIN-RESISTANT MYCOBACTERIUM-TUBERCULOSIS AND MAIS-COMPLEX MYCOBACTERIA [J].
DICKINSON, JM ;
MITCHISON, DA .
TUBERCLE, 1987, 68 (03) :177-182
[5]   MULTIDRUG-RESISTANT TUBERCULOSIS [J].
DOOLEY, SW ;
JARVIS, WR ;
MARTONE, WJ ;
SNIDER, DE .
ANNALS OF INTERNAL MEDICINE, 1992, 117 (03) :257-259
[6]   THE EMERGENCE OF DRUG-RESISTANT TUBERCULOSIS IN NEW-YORK-CITY [J].
FRIEDEN, TR ;
STERLING, T ;
PABLOSMENDEZ, A ;
KILBURN, JO ;
CAUTHEN, GM ;
DOOLEY, SW .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (08) :521-526
[7]   PERMEABILITY BARRIER TO RIFAMPIN IN MYCOBACTERIA [J].
HUI, J ;
GORDON, N ;
KAJIOKA, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1977, 11 (05) :773-779
[8]   Characterization of rifampicin-resistant Mycobacterium tuberculosis in Taiwan [J].
Hwang, HY ;
Chang, CY ;
Chang, LL ;
Chang, SF ;
Chang, YH ;
Chen, YJ .
JOURNAL OF MEDICAL MICROBIOLOGY, 2003, 52 (03) :239-245
[9]   Characterization of rpoB mutations in rifampin-resistant clinical Mycobacterium tuberculosis isolates from Greece [J].
Matsiota-Bernard, P ;
Vrioni, G ;
Marinis, E .
JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (01) :20-23
[10]   Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations [J].
Moghazeh, SL ;
Pan, X ;
Arain, T ;
Stover, CK ;
Musser, JM ;
Kreiswirth, BN .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (11) :2655-2657